EFFECT OF SIBEPRENLIMAB ON HEMATURIA IN ADULTS WITH IgA NEPHROPATHY: INTERIM ANALYSIS OF THE VISIONARY PHASE 3 TRIAL

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/c0cfdff47960bf6d157c755a4e53b97a.pdf
EFFECT OF SIBEPRENLIMAB ON HEMATURIA IN ADULTS WITH IgA NEPHROPATHY: INTERIM ANALYSIS OF THE VISIONARY PHASE 3 TRIAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Hitoshi
Suzuki
Hitoshi Suzuki shitoshi@juntendo.ac.jp Juntendo University Urayasu Hospital Nephrology Chiba Japan *
Vivek Jha vjha@georgeinstitute.org.in University of Oxford Nephrology Oxford United Kingdom -
Manuel Praga mpragat@senefro.org Hospital 12 de Octubre Nephrology Madrid Spain -
Michael Walsh mwwalsh@mcmaster.ca McMaster University Nephrology Hamilton Canada -
José Suassana jose.suassuna@gmail.com Hospital Universitário Pedro Ernesto Nephrology Rio de Janeiro Brazil -
Fernando Nolasco febnolasco@gmail.com Centro Hospitalar Universitário de Lisboa Central Nephrology Lisbon Portugal -
Yoram Yagil labmomed@bgu.ac.il Ben Gurion University and Barzilai Medical Center Nephrology and Hypertension Ashkelon Israel -
Kenar D. Jhaveri Kjhaveri@northwell.edu Northwell Health and Zucker School of Medicine Kidney Diseases and Hypertension Great Neck, NY United States -
Raphaël Duivenvoorden Raphael.Duivenvoorden@radboudumc.nl Radboud University Nephrology Nijmegen Netherlands -
Lucia del Vecchio lucia.delvecchio@asst-lariana.it Sant’Anna Hospital Nephrology and Dialysis ASST Lariana, Como Italy -
Russell Villanueva villanueva.russ@gmail.com Manila Doctors Hospital Nephrology Manilla Philippines -
Lokesh Shah Lokesh.Shah@otsuka-us.com Otsuka Pharmaceutical Development & Commercialization, Inc. Development & Commercialization Princeton, NJ United States -
Jing Xia jing.xia@otsuka-us.com Otsuka Pharmaceutical Development & Commercialization, Inc. Development & Commercialization Princeton, NJ United States -
Cecile Fajardo Cecile.Fajardo@otsuka-us.com Otsuka Pharmaceutical Development & Commercialization, Inc. Development & Commercialization Princeton, NJ United States -
Jeff Hafkin Jeffrey.Hafkin@otsuka-us.com Otsuka Pharmaceutical Development & Commercialization, Inc. Development & Commercialization Princeton, NJ United States -